Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels

Br J Cancer. 2007 Feb 12;96(3):445-9. doi: 10.1038/sj.bjc.6603596. Epub 2007 Jan 23.

Abstract

The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Butadienes / analysis
  • Cell Line, Tumor
  • Cell Proliferation
  • Extracellular Signal-Regulated MAP Kinases / analysis*
  • Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors*
  • G1 Phase
  • Humans
  • Ki-67 Antigen / analysis*
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
  • Mutation
  • Nitriles / analysis
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation
  • Proto-Oncogene Proteins B-raf / genetics

Substances

  • Biomarkers, Tumor
  • Butadienes
  • Ki-67 Antigen
  • Nitriles
  • Phosphoinositide-3 Kinase Inhibitors
  • U 0126
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Extracellular Signal-Regulated MAP Kinases
  • Mitogen-Activated Protein Kinase Kinases